Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Palatin Technologies has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA).
Subscribe to our email newsletter
The grants are related to four of Palatin’s projects – melanocortin agonists for sexual dysfunction; melanocortin agonists for obesity and related metabolic syndrome; natriuretic peptide mimetic PL-3994 for acute asthma; and subcutaneously-delivered natriuretic peptide mimetic PL-3994 for cardiovascular disease.
Palatin said that it will receive $847,000 immediately and $131,000, 30 days after its fiscal year ending 30 June 2011.
Palatin Technologies is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics.